Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
Sorafenib, a tyrosine kinase inhibitor, is a common first-line therapy for advanced differentiated thyroid cancer (DTC). However, responses are not durable and drug toxicity remains a problem. The objective of the study was to determine the efficacy of salvage therapy after first-line sorafenib fail...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | angličtina |
| Vydáno: |
2014
|
| On-line přístup: | https://doi.org/10.1210/jc.2013-3588 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|